Mirum Pharmaceuticals Inc

NAS:MIRM (USA)  
$ 42.17 +0.44 (+1.05%) 11:09 PM EST
At Loss
P/B:
8.62
Volume:
77.97K
Avg Vol (2M):
397.90K
Trade In:
Volume:
77.97K
At Loss
Avg Vol (2M):
397.90K

Business Description

Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 0.9
Equity-to-Asset 0.35
Debt-to-Equity 1.37
Debt-to-EBITDA -5.24
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.97
Distress
Grey
Safe
Beneish M-Score -2.36
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 50.88
9-Day RSI 45.59
14-Day RSI 46.94
6-1 Month Momentum % 28.35
12-1 Month Momentum % 49.1

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.34
Quick Ratio 3.15
Cash Ratio 2.46
Days Inventory 94.16
Days Sales Outstanding 70.7
Days Payable 43.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.2
Shareholder Yield % -7.89

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 72.68
Operating Margin % -31.26
Net Margin % -32.51
FCF Margin % -8.86
ROE % -41.13
ROA % -15.22
ROIC % -33.22
ROC (Joel Greenblatt) % -882.47
ROCE % -15.04

Financials (Next Earnings Date:2025-02-28 Est.)

MIRM's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MIRM

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Mirum Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 307.028
EPS (TTM) ($) -2.069
Beta 0.65
Volatility % 56.1
14-Day RSI 46.94
14-Day ATR ($) 1.812437
20-Day SMA ($) 43.61375
12-1 Month Momentum % 49.1
52-Week Range ($) 23.14 - 48.89
Shares Outstanding (Mil) 48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mirum Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Mirum Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Mirum Pharmaceuticals Inc Frequently Asked Questions

What is Mirum Pharmaceuticals Inc(MIRM)'s stock price today?
The current price of MIRM is $42.17. The 52 week high of MIRM is $48.89 and 52 week low is $23.14.
When is next earnings date of Mirum Pharmaceuticals Inc(MIRM)?
The next earnings date of Mirum Pharmaceuticals Inc(MIRM) is 2025-02-28 Est..
Does Mirum Pharmaceuticals Inc(MIRM) pay dividends? If so, how much?
Mirum Pharmaceuticals Inc(MIRM) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1